Home / NEWS / Commentary / Top Wall Street analysts bet on these stocks for long-term growth

Top Wall Street analysts bet on these stocks for long-term growth

The logo of Alcon is seen on the throng’s corporate headquarters in Huenenberg, Switzerland, on Monday, Jan. 4., 2010.

Peter Frommenwiler | Bloomberg | Getty Images

As the first quarter of 2021 spirals down, analysts are taking a look at the stocks in their coverage universes and evaluating where they stand during the long term.

Against this backdrop are elevated levels of unemployment and a vaccine rollout that is still in its premature stages, with over two-thirds of adults in the U.S. not yet receiving a single dose.

In such uncertain times, one approach to conclusion stocks poised to deliver long-term growth is to follow the recommendations of analysts with a proven track record of big name.

Using TipRanks analyst forecasting service, which attempts to pinpoint Wall Street’s best-performing analysts based on attainment rate and average return per rating, we checked out recent stock picks from these top analysts.

Here are the best-performing analysts’ five favorite routines right now.   

ALX Oncology

ALX Oncology is an immuno-oncology company that develops therapies designed to block the CD47 checkpoint pathway for cancer patients.

Ignoring the recent sell-off, top H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and a price target of $100 (59% upside potency) on March 22.

Ramakanth tells clients that the negative investor sentiment is due to an unfavorable top line readout from the Slant gradually introduce 3 study of tilsotolimod, a TLR9 agonist from Idera. It should be noted that on March 4, ALX Oncology agreed to a 50/50 joint collaboration with Tallac Therapeutics to forth a TLR9 agonist antibody conjugate targeting signal-regulatory protein alpha (SIRPα), SIRPα TRAAC, as a cancer treatment, with an IND needed to be filed by the end of 2022.

“In our opinion, the market overreacted, as we believe the two programs utilize completely different mechanisms of action though both programs use TLR9 agonists and due to the antediluvian stage of the program, the valuation of SIRPα TRAAC has not yet been baked into ALXO price. Therefore, we believe keep on Friday’s sell-off creates an attractive entry point for long-term investors,” Ramakanth commented.

On top of this, the analyst highlights the factually that ALXO will present full results for ALX148, its high-affinity fusion protein binding to CD47, from the Withdraw 1b studies in patients with gastric and gastroesophageal junction (GEJ) cancers and head and neck squamous cell carcinoma (HNSCC) in mid-2021 and 2H21, severally. The therapy is being evaluated in combination with Roche’s Herceptin and Eli Lilly’s Cyramza in HER2+ gastric/GEJ cancers and Merck’s Keytruda in HNSCC.

As the close by clinical data is promising, “ALX148 data updates in both HNSCC and gastric/GEJ cancers could be near-term catalysts for the customary,” in Ramakanth’s opinion. What’s more, Phase 1 data readouts for ALX148 in high-risk MDS and AML in 4Q21 and 1Q22, respectively, could demonstrate additional catalysts, the analyst notes.

Ranked #117 on TipRanks’ list of best-performing analysts, Ramakanth boasts a 36.3% standard in the main return per rating.


In response to Semtech’s beat and raise quarter, Oppenheimer’s Rick Schafer gave the semiconductor business a thumbs up. To this end, the five-star analyst maintained a Buy rating as well as an $80 price target, which puts the upside the right stuff at 23%.

Looking at the details of the print, sales of $165 million and EPS of $0.51 surpassed the consensus estimates of $158 million and $0.48. Most unique, though, was that LoRa wrapped up 2020 at $88 million, up from $74 million, with the company “accomplishing keynote wins with Amazon Sidewalk and AWS IoT Core network (combined $100 million opportunity).”

“We see these wins yet validating LoRa and its ecosystem. SMTC also announced a partnership with Webee in conjunction with earnings. The Webee act on allows customers to easily connect LoRa devices to MSFT Azure. LoRa cloud services begins aiding this year (2H-weighted) and management expects to win more than 20 cloud customers by EOY,” Schafer noted.

Schafer also stations out that adoption on the rise as LoRa public and private operators increased to 150, tracking to 165 by the end of the year. In extension to LoRa, the analyst argues that 5G and DC will support the “accelerating growth story.”

“LoRa cloud services is tottering to drive future benchmark wins, in our view. LoRa remains SMTC’s top growth/upside driver with developing for a 40%-plus 5-yr CAGR. We remain long-term buyers,” Schafer stated.

Currently tracking a 76% success value and 22.3% average return per rating, Schafer earns the #57 spot on TipRanks’ top analyst ranking.


Happy creator and streaming company CuriosityStream just reported solid subscriber numbers for 4Q20. As of December 31, 2020, the callers had 15 million total subscribers, up 50% year-over-year.

It should be noted that 75% of CURI’s DTC subscribers pay $20 for an annual design, and churn fell 25% year-over-year to 30-month average life. Additionally, the launch of discovery+ on January 4 of this year has had no denying impact on CURI’s subscriber growth during the first quarter.

Needham analyst Laura Martin was impressed, with the top analyst consent her Buy rating and $25 price target as is. This price target suggests 79% upside potential.  

“What we be partial to most about CURI is that it is a streaming company, where the bulk of its revenue comes from corporations around the universe under 5-year contracts. This gives investors visibility and downside protection. For example, CURI stated that 80% of its 2021 annual interest guidance is under contract and highly predictable,” Martin explained.

When it comes to the total hours in CURI’s library, mercilessly 30% is entirely owned by CURI while 70% is licensed under three-five year contract terms, with it set to stand by this mix. According to management, there hasn’t been upward pressure on rights costs for licensed content.

Also turn out in the company’s favor is that it completed two sponsorship deals during the fourth quarter, reflecting a new revenue stream, communicates Martin, with the analyst estimating these deals will add $5 million to revenue in 2021 and $7 million to $10 million to gain in 2022.

Landing among the top 65 analysts tracked by TipRanks, Martin has achieved a 64% success rate and 32% mean return per rating.


Following a major 4Q20 beat, Bank of America Securities analyst Nat Schindler handed Parvenue an upgrade, with the rating being changed from Neutral to Buy. Further demonstrating his optimism, he increased the price quarry from $57 to $135. This new target puts the upside potential at 13%.

Easily exceeding the Street’s expectations, returns for the quarter came in at $84.4 million, versus the $79 million consensus estimate. EBITDA of $15.5 million thrash the $11.1 million estimate. Although Upstart posted EPS of $0.00, analysts had originally called for a loss of $0.07.

This imposing showing was driven by a smaller than expected impact by Credit Karma’s November adjustments, high lending mass at 123,396 loans, up 57% year-over-year, and higher conversion rate at 17.4%, up from 14.9% in 4Q19.    

“We are encouraged by Upstart’s talents to deliver 39% growth on tough comps as continued validation of Upstart’s value proposition to both bank fellow-dancers and consumers. We think Upstart could see longer term growth through recurring borrowers and commentary on the call proposes a robust bank partner pipeline going forward,” Schindler said.

Since the company made its public peddle debut in December, it has signed on three new banks, bringing the total number of bank partners to 15. What’s more, the associates just revealed that it is set to acquire Prodigy, automotive retail software company.

“Although we don’t expect material contribution to net incomes in 2021, we see the Prodigy acquisition as a major step forward in Upstart’s expansion into the adjacent TAM of Auto loans (gauged $626 billion),” Schindler commented.

Going forward, management estimates that FY21 revenue will crop up b grow in at $500 million, compared to the $427 million consensus estimate.

According to TipRanks, Schindler is tracking a 59% triumph rate and 22% average return per rating.


In a recent research note, BTIG analyst Ryan Zimmerman lists that multiple product initiatives, a recovery boost and clarity on long-term goals should help investors “see 20/20 in 2021,” when it comes to Alcon.

With this in positive, the five-star analyst upgraded the rating to Buy, with the analyst also assigning a $78 price target (13% upside the right stuff) for the eye care product provider.

Zimmerman acknowledges the fact that since the company was spun out from Novartis in 2019, allots have underperformed the S&P 500 even though it boasts a “healthy valuation premium and beating expectations in three of the last four quarters.” Some investors acquire expressed concern about ALC’s ability to expand operating margins, with the pandemic also hampering the ophthalmology while more than other medical technology sectors.

To this, Zimmerman responded, “However, ALC enters FY21 with a catalogue of top-line drivers and is a beneficiary of recovery dynamics (evident in our surveys and KOL calls), and we expect mgmt.to ‘put to bed’ questions around long-term aims at the Capital Markets Day.”

Although the analyst realizes that operating margins are a cause for concern, Zimmerman argues “it’s not a issue of if ALC gets to low-20s operating margin, but when; we think the difference of a year or more (due to COVID) isn’t prohibitive from owning cuts that are likely to see continued above-market growth, which begins to drive operating leverage over the coming years.”

When it show up to key growth drivers in 2021, the analyst expects patients to return to ophthalmologist and optometry visits, more people to pursue optical solutions to counter the negative effects of increased screen time, a recovery in cataract and refractive surgery amounts, the adoption of AT-IOLs to continue, and hospital budgets to return to the benefit of surgical equipment.

With a 62% success status and 34.7% average return per rating, Zimmerman is ranked #110 on TipRanks’ list.

Check Also

Insana: Yellen is right to hint that higher rates are on the horizon

Ci-devant Federal Reserve Board Chairwoman Janet Yellen discusses monetary policy and the economic outlook at …

Leave a Reply

Your email address will not be published. Required fields are marked *